Doer Biologics

Executive Summary

Doer Biologics is a clinical-stage biotechnology company based in Suzhou, China, founded in 2018 with a focus on developing innovative monoclonal and bispecific antibodies for oncology and autoimmune diseases. The company emphasizes translational research to bridge discovery and clinical development, and has built a robust pipeline with candidates advancing into clinical trials. With a team of 50-200 employees, Doer Biologics is positioned to address significant unmet medical needs in cancer and autoimmune indications through its novel antibody engineering platform. As a Phase 1-stage private company, Doer Biologics is currently advancing its lead candidates through early clinical trials. The biotech sector in China is rapidly evolving, and Doer Biologics benefits from a strong emphasis on R&D and strategic partnerships. While specific pipeline details are limited, the company's commitment to translational research suggests a data-driven approach to clinical development. Key upcoming catalysts include initial safety and efficacy readouts from Phase 1 studies, which will be critical for validating the platform and advancing to later-stage trials. The company's progress will depend on successful enrollment and positive clinical data.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Safety and Efficacy Data Readout for Lead Antibody Candidate40% success
• Q2 2027IND Filing for Second Pipeline Candidate50% success
• TBDPotential Partnership or Licensing Deal30% success